Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Priscilla Leibel

Nurse Practitioner San Antonio, TX Nurse Practitioner

NPI 1730652439 CMS profile 10515217

855 Proton Rd, San Antonio, TX 78258

Open in the dashboard

General payments

$11,689

481 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Priscilla Leibel of San Antonio, TX is reported in the CMS Open Payments database as having received $11,689 across 481 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,522 158
2024 General $3,357 139
2023 General $3,222 134
2022 General $1,587 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Priscilla Leibel
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Priscilla Leibel were reported at $3,522. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Priscilla Leibel Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $1,587 $152 $48–$470 $149
2023 $3,222 $166 $54–$529 $160
2024 $3,357 $173 $55–$556 $164
2025 $3,522 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $3,006 118 payments
  2. Janssen Biotech, Inc. $1,603 65 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,262 74 payments
  4. Genzyme Corporation $806 23 payments
  5. Phathom Pharmaceuticals, Inc. $712 20 payments
  6. Regeneron Healthcare Solutions, Inc. $499 17 payments
  7. Ardelyx, Inc. $455 13 payments
  8. Pfizer Inc. $377 21 payments
  9. Madrigal Pharmaceuticals $371 10 payments
  10. Lilly USA, LLC $359 18 payments
  11. Other $2,239 102 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $11,628 480 payments
  2. Education $61 1 payment
Products named General payments · program years 2022–2025
  1. RINVOQ $1,611 70 payments
  2. STELARA $1,103 43 payments
  3. SKYRIZI $1,090 34 payments
  4. XIFAXAN $877 56 payments
  5. DUPIXENT $806 23 payments
  6. TREMFYA $626 23 payments
  7. VOQUEZNA $607 13 payments
  8. IBSRELA $455 13 payments
  9. TRULANCE $384 18 payments
  10. REZDIFFRA $371 10 payments
  11. Other $4,842 246 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

871

Median for Nurse Practitioner: 389

Drug cost

$60,573

Median for Nurse Practitioner: $21,885

Branded share of claims

23%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 26 $28,728
Dexlansoprazole Dr Dexlansoprazole Brand 27 $9,864
Omeprazole Generic 200 $3,311
Colesevelam Hcl Generic 22 $3,180
Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine Brand 89 $3,162
Pantoprazole Sodium Generic 185 $3,051
Mesalamine Generic 12 $1,978
Famotidine Generic 105 $1,744
Ondansetron Odt Ondansetron Brand 58 $1,253
Esomeprazole Magnesium Generic 17 $1,093

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$39,548

Medicare's payments for the services billed

Medicare patients

393

Average age 74

Services billed

566

232 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 35%
Diabetes 32%
Chronic kidney disease 26%
Depression 22%
Osteoporosis 19%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $345
  • Regeneron Healthcare Solutions, Inc. $189
$535 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $350
$350 — —
STELARA
  • Janssen Biotech, Inc. $324
$324 — —
SKYRIZI
  • AbbVie, Inc. $247
$247 — —
IBSRELA
  • Ardelyx, Inc. $245
$245 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

481 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record